Oxervate (cenegermin-bkbj)
Coverage policy for Oxervate (cenegermin-bkbj) for members (Medicaid scope) specifying clinical criteria for approval, quantity limits, and duration for treatment of persistent epithelial defects/corneal ulceration related to neurotrophic keratitis.
Reviewed on 3/2026 with no material clinical policy statement changes indicated in document header.